Drug-resistant TB: latest news

Drug-resistant TB resources

  • Multidrug-resistant tuberculosis

    Some strains of tuberculosis have become resistant to some of the standard drugs. These multidrug-resistant (MDR) strains have infected both people with HIV and HIV-negative...

    From: HIV treatments directory

    Information level Level 4
  • Drug-resistant TB

    TB that is resistant to isoniazid and rifampicin, and to other drugs as well, is becoming much more common. This is called multidrug-resistant TB (MDR-TB)...

    From: Booklets

    Information level Level 2

Drug-resistant TB features

Drug-resistant TB news from aidsmap

More news

Drug-resistant TB news selected from other sources

  • Preliminary Data Show High Success Rate for Dramatically Shortened Multidrug-resistant TB Treatment Option

    A nine-month treatment regiment for multidrug-resistant tuberculosis (MDR-TB) appears to be as effective as a 12-month regiment, according to data from two new studies being presented today at the 45th World Conference on Lung Health in Barcelona, Spain.

    31 October 2014 | International Union Against Tuberculosis and Lung Disease
  • WHO interim guidance on the use of delamanid in the treatment of MDR-TB

    A new TB drug with a novel mechanism of action – delamanid - is now available for treatment of adults with multidrug-resistant tuberculosis (MDR-TB). Delamanid was granted conditional approval by the European Medicine Agency in April 2014. Information about this new drug however remains limited, since it has only been through Phase IIb trial and studies for safety and efficacy. WHO is therefore issuing “interim policy guidance” that lists five conditions that must be in place if delamanid is used to treat adults with MDR-TB

    29 October 2014 | World Health Organization
  • Success short treatment against drug-resistant tuberculosis confirmed

    In what has become known as the Bangladesh regimen, ITM’s Armand Van Deun and colleagues developed a treatment of only 9 months. This regimen replaces the currently recommended treatment of 18 to 24 months. In 2010, the researchers reported that this treatment increased the success rate from 65% to 88% for MDR-TB patients in Bangladesh. The treatment is based on a combination of existing drugs.The researchers report a favourable outcome in roughly 85% of cases, in spite of increasing levels of serious second-line drug resistance. A smaller study in Niger confirmed the outstanding results of the shorter treatment.

    28 October 2014 | Institute of Tropical Medicine
  • UNITAID’s EXPAND-TB and TBXpert MTB-RIF Projects Detect Over A Quarter of all MDR-TB Cases

    UNITAID welcomes new data in the World Health Organization’s new global report on tuberculosis (TB) which shows a 30% increase in case detection of multi-drug resistant TB (MDR-TB) in 2013, much of which is attributed to the roll out of the UNITAID-funded EXPAND-TB and TBXpert projects. UNITAID’s EXPAND-TB project enabled the installation of sophisticated testing platform technology in TB reference laboratories across 27 countries, bearing 40% of the MDR-TB burden. This provided the capability to detect MDR-TB for the first time for many countries.

    27 October 2014 | UNITAID
  • Drug-resistant tuberculosis poses global threat, warn doctors

    World Health Organisation says spread of hardier strains of TB across former USSR nations is of ‘critical concern’.

    22 October 2014 | The Guardian
  • South Africa: Bedaquiline approved to treat multi-drug resistant tuberculosis

    The Medicines Control Council has approved Janssen Pharmaceutica's bedaquiline, the first drug specifically designed for treating multi-drug resistant tuberculosis (MDR-TB) to reach the market. Janssen is a subsidiary of Johnson & Johnson.

    21 October 2014 | Business Day
  • Minsk has extremely high levels of drug-resistant TB, a study in Belarus reveals

    Multidrug-resistant (MDR)-TB was found in 35.3% (95% CI 27.7–42.8) of new patients and 76.5% (95% CI 66.1–86.8) of those previously treated. Overall, nearly one in two patients enrolled had MDR-TB. Extensively drug-resistant TB was reported in 15 of the 107 MDR-TB patients (14.0%, 95% CI 7.3–20.7). The findings of this survey in Minsk city are alarming and represent the highest proportions of MDR-TB ever recorded in the world.

    29 September 2014 | TB Europe Coalition
  • What does new drug PaMZ mean for TB and HIV treatment?

    The development of PaMZ has been hailed as a breakthrough. But what do the experts think?

    02 September 2014 | The Guardian
  • Acquired rifampicin resistance more likely in HIV-coinfected patients

    Patients with HIV and tuberculosis were more likely to develop acquired rifampicin resistance when treated with a thrice-weekly tuberculosis treatment compared with patients not coinfected with HIV, according to researchers from the National Institute for Research in Tuberculosis in India. The rate of bacteriologic failure was 4% among patients without HIV. Among patients with HIV, the rates were 9% for those not receiving ART and 5% for those receiving ART.

    02 September 2014 | Healio
  • Apathy in TB fight: The Economist Intelligence Unit

    A new report on tuberculosis calls for raising the profile of TB, fight apathy and lack of compelling ambition in addressing the disease.

    04 July 2014 | Stop TB Partnership
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also